KEAP1 and non-small cell lung carcinoma: It mainly interacts with the transcriptional activity of ARE and prevents the combination of the two, thereby inhibiting Nrf2 and overcoming the drug resistance of NSCLC cells due to Keap1 deficiency to carboplatin and other chemotherapy drugs (211).